BACKGROUND AND OBJECTIVES: Adjuvant chemotherapy for stage II colon cancer remains controversial but may be considered for patients with high-risk features. Recent studies have shown that elevated neutrophil to lymphocyte ratio (NLR) is a worse prognostic factor and a predictor of response to chemotherapy in patients with advanced colorectal cancer. The purpose of this study was to evaluate whether NLR predicts risk of recurrence in patients with stage IIA colon cancer undergoing curative resection without adjuvant chemotherapy. METHODS: We retrospectively reviewed 141 consecutive patients with stage IIA colon cancer treated with curative surgery alone from 2002 to 2006. NLR, as well as demographics, clinical, histopathologic, and laboratory data were analyzed. Univariate and multivariate analyses were conducted to identify prognostic factors associated with recurrent-free survival (RFS). RESULTS: Cox's regression analysis demonstrated that elevated NLR (>4) (hazard ratio, 4.88; P < 0.01) and less lymph node sampling (<15 lymph nodes; hazard ratio, 3.80; P < 0.05) were adverse prognostic factors for RFS. The 5-year RFS was 91.4% (95% CI, 88.6-94.2%) for patients with normal NLR and 63.8% (51.1-76.3%) for patients with elevated NLR. The 5-year RFS for patients with 0, 1, and 2 of the identified risk factors was 95.1%, 87.4%, and 33.3%, respectively (P < 0.001). CONCLUSIONS: Elevated preoperative NLR is an independent predictor of worse RFS for patients with stage IIA colon cancer and a potential biomarker to identify candidates for adjuvant chemotherapy.
BACKGROUND AND OBJECTIVES: Adjuvant chemotherapy for stage II colon cancer remains controversial but may be considered for patients with high-risk features. Recent studies have shown that elevated neutrophil to lymphocyte ratio (NLR) is a worse prognostic factor and a predictor of response to chemotherapy in patients with advanced colorectal cancer. The purpose of this study was to evaluate whether NLR predicts risk of recurrence in patients with stage IIA colon cancer undergoing curative resection without adjuvant chemotherapy. METHODS: We retrospectively reviewed 141 consecutive patients with stage IIA colon cancer treated with curative surgery alone from 2002 to 2006. NLR, as well as demographics, clinical, histopathologic, and laboratory data were analyzed. Univariate and multivariate analyses were conducted to identify prognostic factors associated with recurrent-free survival (RFS). RESULTS: Cox's regression analysis demonstrated that elevated NLR (>4) (hazard ratio, 4.88; P < 0.01) and less lymph node sampling (<15 lymph nodes; hazard ratio, 3.80; P < 0.05) were adverse prognostic factors for RFS. The 5-year RFS was 91.4% (95% CI, 88.6-94.2%) for patients with normal NLR and 63.8% (51.1-76.3%) for patients with elevated NLR. The 5-year RFS for patients with 0, 1, and 2 of the identified risk factors was 95.1%, 87.4%, and 33.3%, respectively (P < 0.001). CONCLUSIONS: Elevated preoperative NLR is an independent predictor of worse RFS for patients with stage IIA colon cancer and a potential biomarker to identify candidates for adjuvant chemotherapy.
Authors: Jantine L Westra; Michael Schaapveld; Harry Hollema; Jelle P de Boer; Marian M J Kraak; Debora de Jong; Arja ter Elst; Nanno H Mulder; Charles H C M Buys; Robert M W Hofstra; John T M Plukker Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond Journal: Ann Surg Date: 2009-07 Impact factor: 12.969
Authors: Robert M Strieter; Marie D Burdick; Javier Mestas; Brigitte Gomperts; Michael P Keane; John A Belperio Journal: Eur J Cancer Date: 2006-02-28 Impact factor: 9.162
Authors: Lai Mun Wang; David Kevans; Hugh Mulcahy; Jacintha O'Sullivan; David Fennelly; John Hyland; Diarmuid O'Donoghue; Kieran Sheahan Journal: Am J Surg Pathol Date: 2009-01 Impact factor: 6.394
Authors: W Schippinger; H Samonigg; R Schaberl-Moser; R Greil; R Thödtmann; J Tschmelitsch; M Jagoditsch; G G Steger; R Jakesz; F Herbst; F Hofbauer; H Rabl; P Wohlmuth; M Gnant; J Thaler Journal: Br J Cancer Date: 2007-09-25 Impact factor: 7.640
Authors: Christos Perisanidis; Gabriela Kornek; Paul W Pöschl; Daniel Holzinger; Katharina Pirklbauer; Christian Schopper; Rolf Ewers Journal: Med Oncol Date: 2013-01-06 Impact factor: 3.064